Additionally, it supports your bodys response to insulin and helps decrease excess sugar production, contributing to better metabolic health
Emerging research shows they may help decrease neuroinflammation, particularly in diseases like Alzheimers and Parkinsons
ALDH, Aldehyde dehydrogenase
All of that information appeared in the first 116 words of the STAT story
Start your intake What Clinical Evidence Shows About GLP-1 and Long-Term Use Major clinical trials, including SUSTAIN-6 for semaglutide and SURMOUNT studies for tirzepatide, followed patients for 68 weeks to over two years

Home Medical news & Guidelines Anesthesiology Cardiology and CTVS Critical Care Dentistry Dermatology Diabetes and Endocrinology ENT Gastroenterology Medicine Nephrology Neurology Obstretics-Gynaecology Oncology Ophthalmology Orthopaedics Pediatrics-Neonatology Psychiatry Pulmonology Radiology Surgery Urology Laboratory Medicine Diet Nursing Paramedical Physiotherapy Health news Fact Check Bone Health Fact Check Brain Health Fact Check Cancer Related Fact Check Child Care Fact Check Dental and oral health fact check Diabetes and metabolic health fact check Diet and Nutrition Fact Check Eye and ENT Care Fact Check Fitness fact check Gut health fact check Heart health fact check Kidney health fact check Medical education fact check Men's health fact check Respiratory fact check Skin and hair care fact check Vaccine and Immunization fact check Women's health fact check AYUSH State News Andaman and Nicobar Islands Andhra Pradesh Arunachal Pradesh Assam Bihar Chandigarh Chattisgarh Dadra and Nagar Haveli Daman and Diu Delhi Goa Gujarat Haryana Himachal Pradesh Jammu & Kashmir Jharkhand Karnataka Kerala Ladakh Lakshadweep Madhya Pradesh Maharashtra Manipur Meghalaya Mizoram Nagaland Odisha Puducherry Punjab Rajasthan Sikkim Tamil Nadu Telangana Tripura Uttar Pradesh Uttrakhand West Bengal Medical Education Industry GLP-1 Agonists can reduce risk of mortality, liver failure in patients with type 2 diabetes and cirrhosis Taiwan: A recent population-based cohort study published in Clinical Gastroenterology and Hepatology has revealed multiple benefits of glucagon-like peptide-1 receptor agonist (GLP-1 RA) in patients with type 2 diabetes and compensated liver cirrhosis
